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Cessation of the fMLF-induced burst of human monocyte superoxide release was associated with a rise in CAMP. This 
was not due to inhibition of phophodiesterase (PDE), the major form of which was the PDE IV isozyme. The action 
of burst inhibitors did not correlate with CAMP levels: Rolipram, a PDe IV inhibitor, increased CAMP 6-fold, with mini- 
mal effects on the burst; whereas theophylhne increased CAMP less than 2-fold but decreased the burst to less than half. 
Although theophylline and the adenylate cyclase activator, adenosine, inhibited lMLF-induced superoxide release, they 
did not inhibit production of inositol phosphates. Thus, these studies on inhibition of superoxide release implicated nei- 
ther CAMP nor inositol phosphates. 
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1. INTRODUCTION 
Addition of the chemotactic peptide, fMLF, to a 
suspension of human monocytes causes a burst of 
superoxide release, which ceases in approx. 3 min 
[I]. This is associated with a rise in cellular CAMP, 
which occurs within the first minute of the burst. 
The cause of the increase in cell CAMP has not been 
established. The two obvious possibilities are ac- 
tivation of adenylate cyclase or inhibition of cyclic 
nucleotide phosphodiesterase (PDE). Neutrophil 
adenylate cyclase is not activated by fMLF [2]. 
Adenosine, which activates adenylate cyclase via 
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Az receptors, causes a synergistic rise in the CAMP 
content of fMLF-stimulated human monocytes [3]. 
This suggests that the fMLF-induced increase in 
CAMP may be via inhibition of PDE. In this 
report, we address the question directly by measur- 
ing PDE activity in extracts of human monocytes. 
We also evaluated the possibility that a rise in 
CAMP leads to diminished superoxide release in 
monocytes. This is suggested by the adenosine 
data, since the synergistic rise in CAMP of fMLF- 
stimulated adenosine-treated monocytes is 
associated with depressed superoxide release. We 
first determined the inhibitor sensitivity of PDE ex- 
tracted from human monocytes. The PDE in- 
hibitors or the adenylate cyclase activator, 
adenosine, were then used to increase cellular 
CAMP in the presence and absence of fMLF. 
Cellular CAMP and superoxide release were 
measured to determine if there was a correlation 
between CAMP levels and inhibition of superoxide 
release. 
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2. MATERIALS AND METHODS 2.4. Inositol phosphate production 
2.1. Reagents 
fMLF was from Peninsula Laboratories, Belmont, CA. 
Theophylline, type IV cytochrome c from horse heart, superox- 
ide dismutase, CAMP, and Ophiophagus hannah venom were 
from Sigma, St. Louis, MO. AG l-X8 resin was from Bio-Rad, 
Richmond, CA. HBSS, Gey-BSA and RPM1 1640 culture 
medium were prepared at the Frederick Cancer Research Facili- 
ty. Fetal bovine serum, obtained from Sterile Systems, Logan, 
UT, was heated at 56°C for 30 min before use. [2,8-3H]cAMP 
(spcc. act. 36.1 Ci/mmol) and RIANEN CAMP “‘1 RIA kits 
were obtained from New England Nuclear, Boston, MA. PCS 
scintillation fluid was from Amersham, Arlington Heights, IL. 
Rolipram was a gift from Schering AG, Berlin. CI-914 and 
CI-930 were gifts from Dr R. Weishaar, Warner-Lambert Co., 
Ann Arbor, MI. Ro 20-1724 was a gift from Dr P.F. Sorter, 
Hoffmann-La Roche Inc., Nutley, NJ. 
Monocyte suspensions (5 x 107-1 x 10’ cells per ml) were in- 
cubated at 37°C in Gey-BSA containing 50 &i [3H]inositol per 
ml. Cells were washed three times with Gey-BSA and resus- 
pended in HBSS at 1 x 10’ per ml; 2OOpl aliquots were in- 
cubated with agents as described below. Incubations were stop- 
ped with 400 ,ul of 0.4% perchloric acid. After centrifugation of 
precipitated protein, supernatants were neutralized with KOH 
and KHCOs. Inositol phosphates were fractionated on an 
AG 1X8 (formate) column [6] and radioactivity was measured 
as above. 
3. RESULTS 
2.2. Superoxide production 
Blood monocytes were collected from normal human sub- 
jects, separated by elutriation, stored overnight at 4°C and in- 
cubated at 37°C for 3 h to regain maximal responsiveness [3]. 
Superoxide production was measured as superoxide dismutase- 
inhibitable reduction of cytochrome c by an end-point assay. 
Monocytes, 4 x 10’ per assay, were preincubated for 10 min at 
37°C in 1.5 ml polypropylene microcentrifuge tubes containing 
0.9 ml of 0.11 mM cytochrome cin HBSS. Reference tubes con- 
tained 20~1 of 3 mg/ml superoxide dismutase. Superoxide 
generation was induced by addition of 10 ~1 of 10m4 M fMLF. 
After 7 min at 37”C, suspensions were cooled in ice for 3 min 
and then centrifuged in an Eppendorf microfuge. The 550 nm 
absorbance of supernatants was recorded. Theophylline and 
Rolipram were present throughout the incubations where in- 
dicated. Adenosine was added 2 min before WLF. 
The predominant form of monocyte PDE was 
the PDE IV isoenzyme (nomenclature of Reeves et 
al. [7]) based on inhibitor sensitivity and K,,, for 
CAMP. Table 1 shows that the ability of the cell 
homogenate to hydrolyze 1 pM CAMP was potent- 
ly inhibited by both Rolipram and Ro 20-1724 
(specific inhibitors of PDE IV), but not by CI-914 
or CI-930 (specific inhibitors of PDE III isoen- 
zyme). Dose-response curves for both Rolipram 
and Ro 20-1724 were similar in shape to those of 
the non-specific inhibitors theophylline and iso- 
butyl methyl xanthine, indicating that type IV was 
the predominant isoenzyme and there was no 
significant Rolipram- or Ro 20-1724-insensitive 
component. The K,,, for CAMP was 2.9 PM. 
2.3. PDE assay 
Monocyte homogenates were obtained by osmotic shock, 
followed by extrusion of suspensions 3times through a 30 gauge 
needle. For experiments on the effect of fMLF on PDE activity, 
incubations were stopped by rapidly freezing the cell suspen- 
sions and making the homogenates in 3 vols 50 mM &glycero- 
phosphate, 15 mM NaF and 1 mM phenylmethylsulfonyl 
fluoride. These procedures were shown microscopically to break 
all cells. CAMP PDE activity was assayed by a modification [4] 
of the method of Thompson and Appleman [5]. Each assay mix- 
ture contained cell homogenate, 40 mM Tris-HCl, pH 8.0, 
5 mM MgCh, 3.75 mM 2-mercaptoethanol, 0.1 PM CAMP and 
0.2 &i [3H]cAMP in a total volume of 100 /I. For determina- 
tion of Km values, total CAMP was varied at constant total 
radioactivity. Mixtures were incubated at 37°C for 30 min 
(5 ‘-AMP production rate being constant over this period) and 
stopped by 3 min immersion in a boiling water bath. The 
5 ‘-AMP produced was converted to adenosine by incubation 
with 25 ~1 of 1 mg/ml 0. hannah venom before separation from 
unreacted CAMP by elution from a 1 ml column of AG 1X8 
(Cl-) with 0.1 M NaHCOs. Eluted radioactivity was measured 
in PCS scintillation fluid on a Beckman LS7800 scintillation 
counter. 
To determine if fMLF affected PDE activity, 
PDE was prepared from fMLF-stimulated mono- 
cytes at several time points over a 10 min period, 
during which superoxide generation and a rise and 
fall in CAMP occur. To avoid proteolysis and 
alterations in phosphorylation state, cells were 
homogenized in phenylmethylsulfonyl fluoride, 
NaF and @-glycerophosphate. Fig.1 shows that 
fMLF did not alter PDE activity. The level re- 
mained at approx. 5 pmol/min per lo6 cells. 
Table 1 
Inhibitor sensitivity of monocyte PDE activitf 
Inhibitor ECso (/rM) 
Theophylline 300 
Isobutyl methyl xanthine 16 
Rolipram 2.7 
Ro 20-1724 7.2 
CI-914 >200 
CI-930 >200 
a Substrate: 1 FM CAMP 
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Fig. 1. Effect of fMLF on the PDE activity of human mono- 
cytes. Cells were preincubated for 10 min before the addition of 
10v6 M fMLF. PDE activity was normalized to percentage of 
appropriate control activity. PDE activity at zero time was 
5.4 f 1.4 pmol/min per lo6 cells. 
Table 2 
Effects of PDE inhibition and adenylate cyclase activation on 
monocyte CAMP and superoxide production 
Incubation conditionsa CAMP Superoxide 
(pmol/ lo6 cells) (e/o control) 
Control 1.1 t 0.2s 
+ fMLF 1.5 + 0.2 (100) 
1.5 mM theophylline 1.4kO.2 
+ fMLFC 3.8 rt 0.6 38 f 10 
40 pM Rolipram 1.8 * 0.2 
+ fMLFc 8.8 f 2.5 8lk 2 
40 ,BM adenosined 1 .I’ 
+ fMLF 2.6’ 45s 
a Monocytes incubated for 10 min before addition of 10m6 M 
NLF; incubation stopped at end of 10 min period or after a 
further 2 min in the presence of low6 M WLF. Data are 
means f SE for 3 experiments 
b CAMP measured by radioimmunoassay [3] 
’ Theophylline or Rolipram present hroughout he incubation 
d Adenosine added 2 min before end of incubation 
’ Adenosine added 2 min before addition of fMLF 
f Data from [3] 
g Data from [1] 
Effects of PDE inhibition and adenylate cyclase 
activation on CAMP generation in the absence and 
presence of fMLF were studied along with the pro- 
duction of superoxide. Concentrations of 
Rolipram (40 PM) and theophylline (1.5 mM) giv- 
ing similar PDE inhibition in cell homogenates 
were chosen for study. Adenylate cyclase was ac- 
tivated via A2 receptors by adenosine. Table 2 
shows CAMP levels and amounts of superoxide 
generated in response to 10m6 M fMLF in the 
presence and absence of the above agents. No cor- 
5or IP 
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Fig.2. Effect of adenosine and theophylline on the fMLF- 
stimulated production of inositol phosphates in human mono- 
cytes. IP, inositol monophosphate; IP2, inositol bisphosphate; 
IP3, inositol trisphosphate. (0) fhJLF alone; (a) fMLF plus 
1.5 mM theophylline, which was present hroughout he prein- 
cubation period; (A) fMLF plus 40 PM adenosine, which was 
added 2 min before WLF. Cells were preincubated for 10 min 
before the addition of 10e6 M WLF. Values are the means from 
3 or 4 experiments. For clarity, error bars are omitted; there 
were no significant differences between values at any time point. 
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relation was seen between the amount of monocyte 
superoxide production and CAMP level. 
Adenosine and theophylline cause a significant 
inhibition of fMLF-induced superoxide produc- 
tion. In neutrophils, superoxide production is 
associated with stimulation of PIPz hydrolysis and 
production of inositol phosphates [8]. Fig.2 shows 
that fMLF stimulates monocyte PIP2 hydrolysis, 
with a peak inositol trisphosphate production at 
approx. 20 s after stimulation. However, despite 
inhibition of superoxide release by adenosine or 
theophylline, neither showed any significant effect 
on the time course of PIP2 hydrolysis. 
4. DISCUSSION 
We have shown by the use of isoenzyme specific 
inhibitors that monocytes contain PDE IV. This 
extends the report of Thompson et al. [9] who 
found that monocytes contain an isoenzyme with a 
Km of 1.3 PM CAMP and no cGMP hydrolytic ac- 
tivity, which are characteristic of PDE IV [9]. 
Grady and Thomas [lo] have reported a similar 
PDE activity in human neutrophils which increased 
in response to stimulation of the cells with fMLF. 
This was a surprising observation in view of the 
fact that MLF leads to an increae in CAMP levels 
in neutrophils [2,1 l] which it has been suggested 
may be mediated by PDE inhibition [2]. We also 
suggested that the rise in CAMP in monocytes could 
be due to inhibition of the PDE in response to 
fMLF [3]. However, in the current study we did not 
detect any change in the PDE activity of monocytes 
over a 10 min period after fMLF stimulation 
(fig. 1) despite a significant rise in CAMP. Further- 
more, the increase in CAMP is dramatically poten- 
tiated by the PDE inhibitor, Rolipram (table 2), in- 
dicating that PDE inhibition is not the mechanism 
by which fMLF induces a rise in CAMP. It is there- 
fore probable that fMLF increases the rate of syn- 
thesis of CAMP, although this is not a direct effect 
on the enzyme [2]. 
Theophylline, a methylxanthine-derived PDE in- 
hibitor, is also a potent inhibitor of superoxide 
generation in monocytes. However the rises in 
CAMP induced by theophylline or adenosine are 
small compared with that produced by the non- 
methylxanthine, PDE IV specific inhibitor, 
Rolipram, which shows only a small inhibition of 
superoxide production. We therefore conclude that 
both adenosine and theophylline, which is struc- 
turally closely related to adenosine, inhibit super- 
oxide generation in monocytes by a mechanism 
that is independent of their ability to increase 
cellular CAMP. Cronstein et al. reached a similar 
conclusion for neutrophils [ 121. 
Neither adenosine nor theophylline altered pro- 
duction of inositol phosphates induced by fMLF 
(fig.2). This suggests that inhibition of superoxide 
production by these agents occurs at a site distal to 
the initial receptor-mediated activation of phos- 
pholipase C. Kato et al. [13] found a small inhibi- 
tion of fMLF-induced inositol phosphate produc- 
tion by PGE2 through a CAMP-dependent 
mechanism, although the major effect was on the 
enzymes involved in the synthesis of PIP2. 
Our data leave two problems unanswered. First, 
the mechanism by which fMLF causes an increase 
in the monocyte CAMP is unknown. It does not ap- 
pear to involve either an inhibition of the PDE or 
a direct activation of adenylate cyclase. It is prob- 
able that the fMLF alters the internal environment 
of the cell in such a way as to cause an indirect ac- 
tivation of the cyclase, possibly involving Ca2+ 
[2,11]. Second, the mechanism of inhibition of 
superoxide generation by adenosine and its 
analogues, including the methylxanthine PDE in- 
hibitors, is also unknown. It does appear to be cer- 
tain, both in monocytes (this report) and neutro- 
phils [12], that the inhibitory effect of adenosine or 
its analogues on superoxide production is not 
mediated by CAMP. 
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